Literature DB >> 23483628

Clinical outcomes of patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesions.

In Sun Ryu1, Jong-Lyel Roh, Kyung-Ja Cho, Sang-wook Lee, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim.   

Abstract

BACKGROUND: We compared clinical outcomes between patients with salivary gland carcinomas preoperatively misdiagnosed as benign lesion and properly diagnosed as malignant lesion.
METHODS: The outcomes were compared between patients with benign lesion and malignant lesion (44 each) on preoperative fine-needle aspiration cytology diagnosis who underwent conservative or radical surgery.
RESULTS: Five-year lesion-free survival (DFS) rates were 86.8% for benign lesion and 76.3% for malignant lesion (p = .128). Surgical extent did not significantly affect locoregional recurrence and DFS (p = .360). Univariate analysis showed that sublingual gland tumor, positive resection margin, and extraparenchymal extension (EPE) were significantly associated with DFS (p < .05 each). On multivariate analysis, EPE remained an independent variable (p = .047, hazard ratio = 6.621, 95% confidence interval = 1.393-31.474).
CONCLUSIONS: The clinical outcomes of patients with salivary gland carcinomas misdiagnosed as benign are relatively favorable. Conservative surgery may be sufficient for patients with low-grade and T1-2 salivary gland carcinomas.
Copyright © 2013 Wiley Periodicals, Inc., A Wiley Company.

Entities:  

Keywords:  diagnosis; outcomes; preoperative cytology; recurrence; salivary gland carcinomas

Mesh:

Year:  2013        PMID: 23483628     DOI: 10.1002/hed.23228

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  1 in total

1.  Oncological outcomes of preoperatively unexpected malignant tumors of the parotid gland.

Authors:  Hanaro Park; Sungjun Han; Sung Joon Park; Young Ho Jung; Soon-Hyun Ahn; Woo-Jin Jeong
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-08-30       Impact factor: 2.503

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.